论文部分内容阅读
目的探讨乌司他汀治疗急性重症胰腺炎(SAP)的临床疗效。方法将68例SAP患者随机分为两组,对照组32例,治疗组36例,均给予常规治疗。对照组:生长抑素250μg/h,持续微泵静脉注入,连续7～10d。治疗组:在应用生长抑素基础上加用乌司他汀20万U加入5%葡萄糖250ml中静脉滴注,2次/d,连续7～10d。结果治疗组总有效率88.9%,对照组总有效率81.3%,两者差异无统计学意义(P>0.05)。结论乌司他汀在治疗SAP上虽有一定的效果,但临床疗效不理想,要临床推广值得商榷。
Objective To investigate the clinical efficacy of ulinastatin in the treatment of acute severe pancreatitis (SAP). Methods Sixty-eight patients with SAP were randomly divided into two groups: control group (32 cases) and treatment group (36 cases), both of which were given routine treatment. Control group: somatostatin 250μg / h, continuous micro-pump intravenous injection, continuous 7 ~ 10d. Treatment group: the application of somatostatin plus ulinastatin 200 000 U added 5% glucose 250ml intravenous infusion, 2 times / d, for 7 to 10 days. Results The total effective rate was 88.9% in the treatment group and 81.3% in the control group. There was no significant difference between the two groups (P> 0.05). Conclusion Although ulinastatin has a certain effect in the treatment of SAP, its clinical curative effect is not satisfactory, so it is worth discussing clinically.